Références Scientifiques Consultez la littérature scientifique qui soutient nos cibles moléculaires et notre approche létale synthétique. octobre 2024 Individualized schedule improves rates and severity of anemia in patients treated with lunresertib, a PKMYT1 inhibitor, and camonsertib, an ATR inhibitor, in the Phase I MYTHIC study Højgaard Et Al. ENA 2024 septembre 2024 Genotypically-selected pan cancer trial of camonsertib with palliative radiation in the treatment of metastatic tumors harboring an ataxia-telangiectasia mutated (ATM) mutation Nancy Lee, Et Al. ASTRO 2024 septembre 2024 Driver alterations in FBXW7, PPP2R1A, CCNE1 confer a poor prognosis in patients with metastatic gynecologic cancers Alison M. Schram, Et Al. AACR Ovarian Research Symposium 2024 septembre 2024 Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF) Benedito A. Carneiro, Et Al. ESMO Congress 2024 août 2024 Low Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Mi Li, Et Al. Cancer Research, August 26 2024 juin 2024 Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study) Zev A Wainberg, Et Al. ESMO Gastrointestinal Cancers Annual Congress 2024 - Abstract 504MO juin 2024 Characterizing intra-tumoral heterogeneity of CCNE1 amplification in ovarian cancer using digital pathology Adam Petrone, Isabel Soria-Bretones, Adrienne Johnson, Et Al. AACR SPECIAL CONFERENCE IN CANCER RESEARCH: EXPANDING AND TRANSLATING CANCER SYNTHETIC VULNERABILITIES mai 2024 Identification and Biosynthesis of an N-Glucuronide Metabolite of Camonsertib Robert Papp, Laird Trimble, Adrian J. Fretland, et al. Drug Metabolism and Disposition mai 2024 ATR inhibitor, camonsertib, dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study) Elisa Fontana, MD, PhD, Ezra Rosen, MD, PhD, et al. Journal of the National Cancer Institute avril 2024 Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas Michael S. Nakazawa, Ian M. Silverman, Victoria Rimkunas, Et Al. Molecular Cancer Therapeutics 12345 Notre pipeline comprend plusieurs programmes de développement. Voir Notre Pipeline
